Several biopsy samples with EGFR-mutant cancers patients have shown mechanisms to explain acquired resistance, including histological transformation from adenocarcinoma to Small Cell Lung Carcinoma (SCLC) which suggests a common cell-type origin for both malignancies. A probable explanation proposes that type-II alveolar cells, the origin cell of some EGFR-mutant adenocarcinomas, also have the potential to become SCLC.[...] on the basis of current evidence, we support standard SCLC therapy for SCLC combined with